Blood biomarkers to help detect and monitor cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, prospective study evaluating blood-based biomarkers, specifically cell-free DNA and extracellular vesicles, for early detection, treatment monitoring, and post-treatment surveillance of cervical cancer. Researchers will collect blood samples and analyze cfDNA and EVs to identify potential biomarker signatures. The study also includes tumor biomarker analysis and patient-reported outcomes to understand the clinical utility of these biomarkers in managing disease. Participants are adult women with histologically confirmed cervical cancer undergoing standard treatments such as surgery, radiotherapy, or chemoradiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Females, over 18 years, with histologically confirmed squamous cell carcinoma or adenocarcinoma of the cervix (stage 1a to 4b)
* Undergo intensive primary surgical treatment, radiotherapy (RT) or chemoradiotherapy (CRT).
* Signed written informed consent

Exclusion Criteria:

* Unable to provide informed consent
* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
* Prior malignancies \<5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ.

Where it's running

• Royal Brisbane and Women's Hospital
  Brisbane, Queensland, Australia Recruiting

Study contacts

• Study coordinator: Andreas Obermair
• Email: a.obermair@uq.edu.au
• Phone: +61 7 3346 5073

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• External and internal radiation plus chemotherapy and immunotherapy for Stage IVB cervical cancer

  This trial will try adding external beam radiation and brachytherapy to chemotherapy (cisplatin and paclitaxel) plus immunotherapy (pembrolizumab and bevacizumab) to see if it is safe and helps people with newly diagnosed Stage IVB cervical cancer.

  Recruiting Phase 1/2 Jonsson Comprehensive Cancer Center · Los Angeles, California and 3 other locations · NCT06543576

• AVA6103 for advanced or metastatic FAP-positive solid tumors

  This study will test whether the experimental IV drug AVA6103 is safe and can help adults with advanced or metastatic FAP-positive cancers such as pancreatic, gastric/GEJ, cervical, or vulvar adenocarcinomas.

  Recruiting at 7 sites Phase 1 Avacta Life Sciences Ltd · Scottsdale, Arizona and 6 other locations · NCT07454642

• Short-course (hypofractionated) versus standard radiotherapy with cisplatin and brachytherapy for locally advanced cervical cancer in Uganda

  This trial tests whether a shorter, higher-dose radiotherapy schedule plus cisplatin and brachytherapy works as well and causes no more serious side effects than the usual longer schedule for women in Uganda with stage IB3–IIIC cervical cancer.

  Recruiting Phase 2 Uganda Cancer Institute · Kampala, Kampala · NCT07276360

• EVOLVE104 for advanced bladder and other squamous cell cancers

  This will try EVOLVE104, an experimental drug, in adults with advanced or metastatic bladder or other squamous cell cancers who have already tried or cannot take standard treatments.

  Recruiting at 16 sites Phase 1 EvolveImmune United, Inc · Duarte, California and 15 other locations · NCT07217171

• ALE.P03 alone for adults with advanced CLDN1-positive solid tumors

  This trial tests whether ALE.P03 given alone is safe and can shrink tumors in adults with advanced CLDN1-positive cancers who have already tried standard treatments.

  Recruiting at 41 sites Phase 1/2 Alentis Therapeutics AG · Phoenix, Arizona and 40 other locations · NCT07169734

• Nectin-4 targeted alpha radiotherapy [225Ac]Ac-AKY-1189 for advanced solid tumors

  This trial will try a Nectin‑4–targeted radioactive drug called [225Ac]Ac‑AKY‑1189 in adults with locally advanced or metastatic solid tumors, including certain bladder, breast, lung, and cervical cancers.

  Recruiting at 14 sites Phase 1 Aktis Oncology, Inc. · Duarte, California and 13 other locations · NCT07020117

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.